

SUMMARY FROM ANNUAL GENERAL MEETING OF EPISURF MEDICAL AB (PUBL)

Episurf Medical AB (publ) (“Episurf” or the “Company”) held its Annual General Meeting (the “Meeting”) on Tuesday, 9 April 2024 in Stockholm.

The income statements and the balance sheets for the Company and the group were approved and the Board of Directors and the CEO were discharged from liability for the financial year 2023.

The Meeting resolved, in accordance with the proposal of the Board of Directors, that the Company shall not pay dividends for the financial year 2023.

The Meeting resolved to approve the remuneration report for the financial year 2023.

In accordance with the proposal by the Nomination Committee, Annette Brodin Rampe, Ulf Grunander, Christian Krüeger, Leif Ryd and Laura Shunk were re-elected as members of the Board of Directors and Jess Lonner was elected as a new member of the Board of Directors. Also in accordance with the proposal by the Nomination Committee, Ulf Grunander was re-elected as Chairman of the Board of Directors.

In accordance with the proposal by the Nomination Committee, the Meeting resolved that total fees of SEK 1,425,000 (SEK 1,225,000) are to be paid to the Board of Directors, of which SEK 400,000 (SEK 400,000) is to be paid to the Chairman of the Board of Directors, SEK 200,000 (SEK 200,000) is to be paid to each of the other board members and SEK 25,000 (SEK 25,000) is to be paid to the Chairman of the Board of Directors’ Audit Committee.

In accordance with the proposal by the Nomination Committee, the registered accounting firm Öhrlings PricewaterhouseCoopers AB was elected as the auditor of the Company, with the authorised public accountant Tobias Strähle as the auditor in charge. The auditors’ fee shall be paid in accordance with approved invoice.

The Meeting approved the Nomination Committee’s proposal on the nomination procedure and instruction for the Nomination Committee for the Annual General Meeting 2025.

The Meeting approved the Board of Directors’ proposal regarding guidelines for remuneration to the senior management.

Finally, the Meeting resolved, in accordance with the proposal of the Board of Directors, on an issue authorisation for the Board of Directors.

Episurf Medical AB (publ)

The Board of Directors

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

The information was submitted for publication, through the agency of the contact person set out above, at 16:30 CEST on 9 April 2024.